Aclaris Therapeutics’ (ACRS) Buy Rating Reaffirmed at HC Wainwright
Aclaris Therapeutics (NASDAQ:ACRS – Get Free Report)‘s stock had its “buy” rating reiterated by stock analysts at HC Wainwright in a research report issued on Wednesday,Benzinga reports. They currently have a $16.00 target price on the biotechnology company’s stock. A number of other equities analysts have also weighed in on the company. Cantor Fitzgerald assumed […]
Aclaris Therapeutics (NASDAQ:ACRS – Get Free Report)‘s stock had its “buy” rating reiterated by stock analysts at HC Wainwright in a research report issued on Wednesday,Benzinga reports. They currently have a $16.00 target price on the biotechnology company’s stock. A number of other equities analysts have also weighed in on the company. Cantor Fitzgerald assumed […]
